Marie-Cecile Didiot

Marie-Cecile Didiot has over 17 years of work experience in the fields of molecular and cellular biology, biochemistry, and research. Marie-Cecile began their career in 2002 as a Bachelor Trainee in Biochemistry at Universite Henri Poincare - lab: AREMS, where they collaborated with Prof. Christiane Branlant on protein production and purification. In 2003, they became a Research Assistant for both their Master and PhD studies at Institut de Genetique et de Biologie Moleculaire et Cellulaire, where they collaborated with Prof. Jean-Louis Mandel and Dr. Herve Moine on the implications of the Fragile X Mental Retardation Protein, FMRP, within translation regulation. In 2008, they joined Novartis Institutes for BioMedical Research (NIBR) as a Postdoctoral Research Associate, where they collaborated with Dr. Christian Parker on developing and implementing chemical screens using cellular models to elucidate compound modes of action and to discover novel targets and leads. In 2013, they moved to University of Massachusetts Medical School - RNA Therapeutic Institute as a Postdoctoral Research Associate, where they collaborated with Prof. Anastasia Khvorova on the use of small oligonucleotides (ASOs, siRNAs, microRNA mimics, and anti-microRNAs) for the silencing of specific disease promoting genes in the treatment of human disease. In 2019, Marie-Cecile joined Flagship Pioneering - VL59 as a Research Scientist. Currently, they are employed as a Principal Scientist Analytical Development and Senior Scientist, RNA Research & Development at Myeloid Therapeutics.

Marie-Cecile Didiot began their educational career in 1998, when they earned their Master's Degree in Biochemistry from Henri Poincare University in Nancy, France. Marie-Cecile then continued their studies at Strasbourg University in France, where they were a PhD Student in Molecular and Cellular Biology from 2003 to 2008.